Skip to main content

COVID-19 Topic Center

Interactive Features

First Report Managed Care
True or False: Criteria for inclusion and exclusion in clinical trials of chimeric antigen receptor T-cell therapy for hematologic malignancies are highly variable and bring to light the need for a more standardized approach to patient enrollment.True or False: Criteria for inclusion and…
First Report Managed Care
By Julie Gould Podcast Series:  In this episode, Steven Albelda, MD, professor of medicine at the University of Pennsylvania, Pulmonary Division, discusses a $10 million grant that Penn Medicine recently received from the National Cancer Institute and explains how a team of…
First Report Managed Care
By Julie Gould Podcast Series: In this episode, Elizabeth Budde, MD, PhD, assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses recommendations that were recently created by a National Comprehensive Cancer Network task force for…
First Report Managed Care
By Zachary Bessette Podcast Series: Gary Goldstein, business manager of the Blood and Marrow Transplant Program at Stanford Health Care, discusses the changes needed for increased CAR-T administration in the outpatient setting as well as commercial and provider concerns about the latest…
First Report Managed Care
By Zachary Bessette Podcast Series: Michael R. Bishop, MD, Director, Cellular Therapy Program, University of Chicago Medicine, discusses the challenges providers face when navigating Medicare and Medicaid policy for administering chimeric antigen receptor (CAR) T-cell therapy as well as…
First Report Managed Care
By David Costill Podcast Series: We discuss the clinical aspects and mechanism of CAR-T therapy for the treatment of hematological malignancies with Nicole Trask, PharmD, a clinical consultant Pharmacist at UMass Medical School.     Podcast Transcript: Hello and welcome back to…
First Report Managed Care
By Dave Costill In this episode of the First Report Managed Care podcast, we spoke with Russell J Spjut, PharmD, about how the emergence of FDA-Approved CAR-T therapies for the treatment of hematological malignancies could impact managed care.   Podcast Transcript Welcome to the First…
Back to Top